IL12B and colitis: Our results indicated that the absence of myeloid STING significantly decreased the levels of Il12b, Il12a, and Il23a in colitis and the deletion of STING in DMXAA-treated BMDMs/BMDCs noticeably suppressed pathways related to the IL-12 family and IL-12/IL-23 production.